Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa?

Guinevere Q. Lee, Suzanne McCluskey, Yap Boum, Peter W. Hunt, Jeffrey N. Martin, David Bangsberg, Xiaojiang Gao, Richard R. Harrigan, Jessica E. Haberer, Mark J. Siedner

Research output: Contribution to journalArticle

Abstract

ABSTRACT: Despite a poor toxicity profile, zidovudine supersedes abacavir as an alternative first-line agent in most international treatment-guidelines due to concerns about HLA-B*57:01-related abacavir-hypersensitivity. We detected one case of HLA-B*57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with prior reports, supports the safety of abacavir in the region.

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
DOIs
StateAccepted/In press - Jun 19 2017

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa?'. Together they form a unique fingerprint.

  • Cite this

    Lee, G. Q., McCluskey, S., Boum, Y., Hunt, P. W., Martin, J. N., Bangsberg, D., Gao, X., Harrigan, R. R., Haberer, J. E., & Siedner, M. J. (Accepted/In press). Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa? Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/QAI.0000000000001487